View source for 20240041900. GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS simplified abstract (The Johns Hopkins University)

=GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS=


==Organization Name==

[[:Category:The Johns Hopkins University|The Johns Hopkins University]]


[[Category:The Johns Hopkins University]]

==Inventor(s)==

[[:Category:Barbara Slusher of Kingsville MD (US)|Barbara Slusher of Kingsville MD (US)]][[Category:Barbara Slusher of Kingsville MD (US)]]

[[:Category:David Volsky of Scarsdale NY (US)|David Volsky of Scarsdale NY (US)]][[Category:David Volsky of Scarsdale NY (US)]]

[[:Category:Mike Nedelcovych of Richmond VA (US)|Mike Nedelcovych of Richmond VA (US)]][[Category:Mike Nedelcovych of Richmond VA (US)]]

[[:Category:Kristen Hollinger of Parkton MD (US)|Kristen Hollinger of Parkton MD (US)]][[Category:Kristen Hollinger of Parkton MD (US)]]

[[:Category:Atsushi Kamiya of Pikesville MD (US)|Atsushi Kamiya of Pikesville MD (US)]][[Category:Atsushi Kamiya of Pikesville MD (US)]]

==GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240041900 titled 'GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS

==Simplified Explanation==

The abstract of the patent application describes a group of compounds and their pharmaceutically acceptable salts for use in treating cognitive deficits and psychiatric disorders associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND). These compounds are prodrugs that release glutamine analogs, specifically 6-diazo-5-oxo-l-norleucine (DON).

* The compounds described in the patent application are prodrugs that release glutamine analogs.
* These compounds and their pharmaceutically acceptable salts can be used to treat cognitive deficits and psychiatric disorders associated with various conditions.
* The specific conditions mentioned include neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND).

Potential applications of this technology:
* Treatment of cognitive deficits associated with neurological or neurodegenerative disorders such as Alzheimer's disease or Parkinson's disease.
* Treatment of psychiatric disorders such as depression, anxiety, or schizophrenia.
* Treatment of HIV-associated neurocognitive disorders (HAND).

Problems solved by this technology:
* Cognitive deficits and psychiatric disorders associated with various conditions can be effectively treated.
* The release of glutamine analogs through prodrugs provides a targeted approach for addressing these disorders.

Benefits of this technology:
* Improved cognitive function and mental well-being for individuals suffering from cognitive deficits and psychiatric disorders.
* Potential for more targeted and effective treatment compared to existing therapies.
* Possibility of addressing multiple conditions with a single compound or class of compounds.


==Original Abstract Submitted==

and the pharmaceutically acceptable salts thereof, wherein r, r, r′, and x are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and hiv-associated neurocognitive disorders (hand). compounds having formula (i) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-l-norleucine (don).



[[Category:A61K31/655]]
[[Category:A61K31/42]]
[[Category:A61K31/223]]
[[Category:A61K31/198]]
[[Category:A61P25/28]]